Hungkuang Professor Wins Gold for Diabetic Wound Healing Drug at Intl. Invention Competition
Exhibitor: HUNGKUANG UNIVERSITY
Date: 2025-05-22
Booth No.: N428
Professor Wan-Yu Lo from the Department of Food Science and Technology at Hungkuang University and her research team have been awarded the Gold Medal at the 2024 PRIX EIFFEL International Invention Competition in France for their innovative product, “Development of a miR-200b-Based Drug to Promote Diabetic Wound Healing.” This research has already received a Taiwanese invention patent and has been published in an international scientific journal.
Professor Lo explained that after four years of dedicated research, her team successfully developed the world’s first diabetic wound treatment drug centered around microRNA-200b. This drug accelerates wound healing in diabetic patients—a crucial breakthrough, given that Taiwan has approximately 2.5 million people living with diabetes. Once commercialized, the product could significantly improve wound care for this large patient population.
Professor Lo is also a member of Hungkuang University's Health and Wellness Center for Humans and Pets. Her expertise spans microRNA applications, drug delivery systems, and animal testing for pharmaceuticals, cosmetics, and pet products, as well as functional analysis, cell culture, and immunology. She noted that during her research involving cellular and animal models, microRNAs showed anti-inflammatory properties, which led her to explore their use in drug development. Given the notoriously slow wound healing process in diabetic patients—who are more susceptible to infections, sepsis, and even amputations—her team decided to target this critical medical need.
The research team included Dr. Huang-Chou Wang from China Medical University Hospital, research assistant Chien-Hui Hsin, and students Hsun-Chih Hsu and Chih-Hsuan Lee from the Baking Technology Division of the Department of Food Science and Technology. The two students assisted in testing the gelation rate of the drug formulation. They expressed their excitement in discovering the joy and sense of accomplishment in research, and felt honored to be part of a project recognized with a prestigious international gold medal.
Professor Lo emphasized that their drug is the first globally to feature miR-200b as the key ingredient for diabetic wound treatment. It not only effectively reduces inflammation but also promotes collagen production and angiogenesis, accelerating wound healing and significantly reducing the risk of amputation. These properties grant the drug tremendous clinical value.
Diabetic foot ulcers (DFUs) are notoriously difficult to treat and have a high incidence rate, posing long-term challenges to patients. This invention offers a practical solution—an easy-to-apply, non-detachable gel that elderly patients can use at home for better wound care.
In addition to the Gold Medal at the PRIX EIFFEL 2024, this innovation has already secured a Taiwanese invention patent and been published in an international journal. Professor Lo remarked that the invention has great potential for clinical applications. The team plans to apply for a U.S. patent and is actively seeking suitable partners for technology transfer to bring the drug to market and offer diabetic patients a novel, effective treatment option—ultimately benefiting more people around the world.
More Exhibitor's Press Release
- GoldenBiotech Seminar:Advancing First-Line Therapy for Metastatic Pancreatic Cancer: Global Phase 3 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-10
- Your Invitation to Innovation – Booth M412 Forum MAJOR SCIENCE CO.,LTD / 2025-07-09
- Cell Bio Biotechnology to Host Three International Authorities at BioAsia 2025, Unveiling a New Era CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-09
- Rooted in Mountains, Climbing the Peaks. BIOMEDICAL TRANSLATION RESEARCH CENTER, ACADEMIA SINICA (NATIONAL BIOTECHNOLOGY RESEARCH PARK) / 2025-07-09
- Honya’s MiSaver: A New Frontier in Treating Heart Damage After Heart Attacks HONYA MEDICAL CO., LTD. / 2025-07-08
- TaiMed Biologics Highlights Integrated CDMO Services at BIO Asia 2025 TAIMED BIOLOGICS INC. / 2025-07-08
- 現場校正、抽檢應用 攜帶式測量儀 XIN TOP CORPORATION / 2025-07-08
- 2025微脂體高值新藥開發 CDMO 產業說明會圓滿成功,業界專家共探創新契機 ZILLION FINE CHEMICAL INTERNATIONAL CO., LTD. / 2025-07-07
- 潤雅生技與日本精化簽署合作備忘錄(MOU) 攜手日隆精化,共拓CDMO業務版圖 ZILLION FINE CHEMICAL INTERNATIONAL CO., LTD. / 2025-07-07
- 日隆精化攜瑞采生技參訪日本精化 助推腎病高值新藥IND微脂體製備 ZILLION FINE CHEMICAL INTERNATIONAL CO., LTD. / 2025-07-07
- Latest Innovations! GeneFerm Collaborates with NTU to Launch: GFRena2, TestoPro, and AquaSoiivon GENEFERM BIOTECHNOLOGY CO., LTD. / 2025-07-07
- GeneFerm Strengthens Anaerobic and Precision Fermentation Capabilities to Advance as a Global-Standa GENEFERM BIOTECHNOLOGY CO., LTD. / 2025-07-07
- GeneFerm Biotechnology – Your Trusted CDMO Partner in Fermentation Technology GENEFERM BIOTECHNOLOGY CO., LTD. / 2025-07-07
- FDA Project Optimus-Impact and Response Strategy EFFICIENT PHARMA MANAGEMENT CORP. / 2025-07-07
- Igus and JYTC walk together for better options. (German beer limited served daily) JYTC CO., LTD. / 2025-07-05
- Seminar JAPAN FOOD RESEARCH LABORATORIES(JFRL) / 2025-07-04
- Next Generations Therapy Manufacturing LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-03
- The Fastest and Safest Depth Filtration LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-03
- Highest Cell Viability in Perfusion LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-03
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 XIN TOP CORPORATION / 2025-07-03